Neoplasms
Conditions
Keywords
[68Ga]P3, PSMA, PET/CT, Neoplasms
Brief summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Detailed description
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.\[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Interventions
DRUG[68Ga]P3
68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Sponsors
Peking University First Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
patients with confirmed or suspected cancer; 18F-FDG PET/CT within 1 week; Signed written informed consent
Exclusion criteria
Pregnant and lactating women; Female patients plan to become pregnant within 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of malignant tumors | 1 year | Compare the standardized Uptake Value (SUV) of lesions on 68Ga-P3 and 18F-FDG PET/CT |
| The detection efficacy of 68Ga-P3 PET/CT in the evaluation of malignant tumors | 1 year | Compare the number of lesions detected by 68Ga-P3 and 18F-FDG PET/CT, based on the pathology or clinical follow-up as gold standard. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The dosimetry of 68Ga-P3 | 1 year | Research on the dose distribution of 68Ga-P3 in healthy volunteers and cancer patients by 1-hour dynamic PET/CT acquisition and analyze by the dosimetry software |
| Quantitative evaluation of 68Ga-P3 | 1 year | Evaluation of quantitative parameters of 68Ga-P3, such as time-activity curve. |
| Correlation with pathological expression | 1 year | Analyze PSMA expression at the imaging level in combination with PSMA expression in pathological specimens |
Countries
China
Contacts
Primary ContactXing Yang, Dr.
Outcome results
None listed